Notwithstanding promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from PBMs. These insurers are frequently creating obstacles to access, like steep price criteria and prior authorization that hinder user access. Market suggest that these